Maria Hafez, Assistant Professor at St. Luke’s University Health Network, shared a post on LinkedIn:
“Monday Breast Cancer Food for Thought
Should we change our practice when it comes to pegfilgrastim timing?
A very practical study by Li et al. asks an important question:
Can simply delaying pegfilgrastim to 72 hours after chemotherapy reduce bone pain without compromising safety?
In this prospective randomized phase 3 trial of patients with stage I–III breast cancer:
- 159 patients were randomized to receive pegfilgrastim at 24, 48, or 72 hours after chemotherapy
- The 72-hour group had significantly less bone pain
- Severe bone pain dropped to 22.6%, compared with 58.5% in the 24-hour group and 66.0% in the 48-hour group
- There was no meaningful difference in neutropenia
- No febrile neutropenia was observed
Why does this matter?
Pegfilgrastim-induced bone pain is not a small issue. It can affect quality of life, create anxiety around treatment, and add yet another burden to patients already navigating chemotherapy. Sometimes the most meaningful advances are not new drugs, but smarter ways to use the tools we already have.
Of course, this was an open-label, single-center study with a relatively small sample size, so caution is warranted before broadly changing routine practice. But it does raise an important question for all of us in breast oncology:
- Should we begin moving toward 72-hour pegfilgrastim administration more routinely, especially for patients who experience significant bone pain?
- Or is this interesting, but not yet enough to change practice?
I would be very interested to hear how others are interpreting this study and whether it has influenced their supportive care approach.”
Title: Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain: A Prospective, Randomized, Phase 3 Trial
Authors: Peiyong Li, Yitian Chen, Yingyi Lin, Xiaoqi Zhang, Minyi Cheng, Teng Zhu, Hong-Fei Gao, Liulu Zhang, Jieqing Li, Na Huang, Yilin Chen, Minting Liang, Yuanqi Zhang, Shengchao Huang, Junqiu Zheng, Cangui Wu, Ciqiu Yang, Kun Wang
Read the Full Article.
Other Articles Featuring Maria Hafez on OncoDaily.